Table 1.
Baseline characteristics of enrolled patients.
| Characteristics | Present | Salles et al. |
|---|---|---|
| Paper (n = 72) | (n = 72) | |
| Median age at diagnosis, years (range) | 57.2 (24.5–82.2) | NA |
| Median age, years (range) | 63.0 (36.4–84.7) | 62 (33.0–84.0) |
| Sex (male), n (%) | 47 (65.3) | 39 (54.2) |
| ECOG < 1, n (%) | 68 (94.4) | 66 (91.7) |
| Stage at diagnosis, n (%) | ||
| I/II | 8 (11.2) | 12 (16.7) |
| III/IV | 64 (88.8) | 60 (83.3) |
| Bone marrow involvement, n (%) | 40 (55.6) | NA |
| LDH > UNL, n (%) | 24 (33.3) * | 21 (29.2) ° |
| FLIPI > 2, n (%) | 41 (56.9) | 57 (79.2) |
| Follicular lymphoma grade 3a, n (%) | 13 (18.1) | 12 (16.7) |
| Median of previous therapy, n (range) | 3 (1–10) | 4 (2–12) |
| Previous ASCT, n (%) | 23 (31.9) | 12 (16.7) |
| Baseline neutropenia | 10 (13.9) | 8 (11.1) |
| Baseline anemia | 9 (12.5) | 8 (11.1) |
| Baseline thrombocytopenia | 7 (9.7) | 5 (6.9) |
| Median time since diagnosis, years (range) | 5.8 (0.5–20) | 4.7 (0.8–18.4) |
| Median time since last relapse, months (range) | 1.6 (0.2–22.9) | NA |
| Refractory (≤6 mo) to the first line of therapy, n (%) | 20 (27.8) | NA |
| Refractory (≤6 mo) to most recent therapy, n (%) | 15 (20.8) | 62 (86.1) |
| Relapsed (>6 mo) to most recent therapy, n (%) | 57 (79.1) | 10 (13.8) |
| Treatment disposition at time of data cutoff, n (%) | ||
| Ongoing | 3 (4.2) | 7 (9.7) |
| Discontinued: | ||
| PD | 31 (43) | 38 (52.8) |
| AE | 24 (33.3) | 15 (20.8) |
| Investigator request | 6 (8.3) § | 4 (5.6) £ |
| Death | 2 (2.7) | 5 (6.9) |
| Withdrew consent | 0 (0) | 3 (4.2) |
AE—adverse event; ASCT—autologous stem cell transplantation; FLIPI—follicular lymphoma international prognostic index; ECOG—Eastern Cooperative Oncology Group; LDH—lactate dehydrogenase; mo—months; NA—not available; PD—progression of disease; UNL—upper normal limit; * defined as >248 U/L; ° defined as >234 U/L. § All six patients in response were referred to stem-cell transplantation, £ including one patient referred to transplant.